Table 3 Treatment exposure by history of calcinosis
From: Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis
| Risk factor | Descriptive analysis | Univariable analysis | |||
|---|---|---|---|---|---|
| Calcinosis | OR [95% CI] | p-value | |||
| Yes | No | ||||
| Biologic treatment (Ever) | n (%) | ||||
| Any biologic | 48 (57.1) | 194 (35.5) | 0.0001 | 2.426 [1.522–3.867] | |
| Rituximab | 12 (14.3) | 14 (2.6) | < 0.0001 | 6.345 [2.825–14.254] | < 0.001 |
| IV Immune Globulin | 45 (53.6) | 180 (32.9) | 0.0002 | 2.353 [1.479–3.743] | 0.0003 |
| Anti-TNF | 12 (14.3) | 23 (4.2) | 0.0009 | 3.797 [1.812–7.960] | 0.0004 |
| Abatacept | 2 (2.4) | 1 (0.2) | 0.048 | 13.317 [1.194–148.514] | 0.0354 |
| Anti-IL1 | 1 (1.2) | 1 (0.2) | |||
| High steroid exposure | 47 (56) | 269 (54.3) | |||